Healthcare · Medical Devices
· website
· 175 employees
$0.26
52wk 0.21 – 0.45
Overall
51.6
Value
78.4
Growth
77.8
Health
36.5
Quality
14.8
Momentum
37.7
Dividend
—
Price
About Compumedics Limited
Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and associated technologies in the Americas, Australia, the Asia Pacific, Europe, and the Middle East. The company provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Grael PSG; Grael 4K PSG; Falcon HST; and Somté, an investigative tool. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG, Grael 4K-EEG, and Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, a portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, it provides software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; CURRY, a signal processing and source localization multi-modal neuroimaging suite; Profusion neXus Scheduler for planning for staff and time; Somte and Persyst Software; HD Digital Video; Profusion Plus; ECG Free software; and TCM5 FLEX Transcutaneous Monitor, Grael DC, Siesta extended battery pack, and Summit IP products. Further, the company offers brain research technologies; pharmaceutical clinical trials and research services; and consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Price analytics
Returns
1 day
8.3%
1 week
8.3%
1 month
10.6%
3 months
-3.7%
6 months
-10.3%
1 year
-13.3%
3 years
36.8%
Risk
Volatility (1y ann.)
75.4%
Beta vs ASX 200
0.57
Sharpe (1y)
0.12
VaR 95% (1-day)
-6.5%
Max drawdown (1y)
-52.2%
Off 1-year high
-42.2%
Technicals
RSI(14)
43
vs 50DMA
8.5%
vs 200DMA
-8.8%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value78.4
Trailing P/E
—
Forward P/E
100
PEG ratio
48
EV / EBITDA
64
Price / Book
86
Price / Sales
100
Growth77.8
Revenue growth (1y)
78
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health36.5
Net debt / EBITDA
34
Interest coverage (EBIT/interest)
0
Current ratio
25
Debt / Equity
77
Quality (Profitability & Cash Flow)14.8
Return on equity
5
Return on assets
38
Operating margin
19
Net margin
2
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum37.7
6-month return vs ASX 200
28
Price vs 200-day average
21
Price vs 50-day average
92
Position in 52-week range
19
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).